Text Size
10 studies found for:    NOT (aplastic OR fanconi OR blackfan OR sickle OR telangiectasia) AND cytopenia | Open Studies | Interventional Studies | anemia | United States

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Sirolimus for Autoimmune Disease of Blood Cells
Conditions: Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
Intervention: Drug: sirolimus
2 Recruiting Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant
Conditions: AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
Intervention: Drug: Abatacept
3 Recruiting Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Paroxysmal Nocturnal Hemoglobinuria;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis
Interventions: Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
4 Not yet recruiting Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Graft Versus Host Disease;   Intraocular Lymphoma;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Central Nervous System Hodgkin Lymphoma;   Secondary Central Nervous System Non-Hodgkin Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: vorinostat;   Drug: tacrolimus;   Drug: cyclosporine;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia
Interventions: Biological: pretargeted radioimmunotherapy;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: fludarabine phosphate;   Other: pharmacological study
6 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: cytogenetic analysis
7 Recruiting Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
Conditions: Anemia;   Hematopoietic/Lymphoid Cancer;   Lymphopenia;   Neutropenia;   Thrombocytopenia
Interventions: Biological: Allogeneic hematopoietic stem cell transplantation;   Biological: Peripheral blood stem cell transplantation;   Procedure: Management of therapy complications
8 Recruiting T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: umbilical cord blood transplantation;   Drug: Allopurinol;   Drug: fludarabine phosphate;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Treg infusion;   Drug: Sirolimus
9 Unknown † Bortezomib in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: bortezomib
10 Recruiting Alemtuzumab (Campath(Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
To Top

† Indicates status has not been verified in more than two years